DWTX Dogwood Therapeutics, Inc.
$1.11▼ -2.63%
Healthcare
Other
Volume 39.5K
Avg Volume (10D) 81.1K
Key Metrics & Fundamentals
Market Cap
$37.73M
P/E Ratio
0.5
Div Yield
0.00%
52W Range
1.07 - 7.04
% vs 50 MA
-36.90%
% vs 200 MA
-44.75%
RSI-14
23.8
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.18
Free Cash Flow
-$3.61M
Gross Rev
$0
Gross Profit
$0
EBITDA
$4.35M
COGS
–
Operating Exp
$4.87M
Operating Income
-$4.87M
EBIT
-$4.87M
Pretax Income
-$14.01M
Net Income
-$11.53M
EPS (Diluted)
-0.34
Price & Volume History
Loading chart…
Recent News
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
GlobeNewswire · Oct 19, 2026 8:30 AM ET
Dogwood to Participate in the 2026 Maxim Growth Summit
GlobeNewswire · Oct 6, 2026 8:45 AM ET
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
GlobeNewswire · Sep 14, 2026 8:45 AM ET
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment
MarketBeat · Sep 1, 2026 6:01 PM ET
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
GlobeNewswire · Aug 17, 2026 8:30 AM ET
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
GlobeNewswire · Aug 13, 2026 8:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See DWTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.